#USA #Bradenton, Florida #Continuity Biosciences #Josephine Torrente #Joseph DeSimone

Continuity Biosciences Expands Board with Strategic Appointments

Continuity Biosciences, a leading firm in next-generation drug delivery systems, has announced the addition of Josephine M. Torrente and Joseph M. DeSimone, PhD, to its board of directors. These appointments are pivotal for the organization as it seeks to advance its mission of developing transformative drug administration technologies.

Who Are the New Board Members?

Josephine M. Torrente

Josephine Torrente serves as a director at Hyman, Phelps & McNamara, P.C., the largest FDA regulatory law firm in the U.S. With over 30 years of experience, she specializes in providing strategic regulatory guidance to pharmaceutical and biotech companies. Her extensive knowledge in FDA regulations and product lifecycle management will be invaluable as Continuity navigates its clinical development strategies and FDA engagement going forward.

Dr. Joseph M. DeSimone

Dr. Joseph M. DeSimone is a distinguished professor at Stanford University, specializing in translational medicine and chemical engineering. His impressive repertoire includes over 200 patents and 350 scientific publications. Dr. DeSimone is also a co-founder of Carbon, which is renowned for its innovative CLIP 3D printing technology. His experience in material science, digital manufacturing, and drug delivery systems will complement Continuity's focus on localized and precision therapies.

Strategic Importance of These Appointments

The additions of Torrente and DeSimone come at a crucial time for Continuity, underpinning its ambitions to enhance its product portfolio. Bob Whitehead, co-founder and Executive Chairman of Continuity Biosciences, expressed enthusiasm regarding the appointments. He noted, "The regulatory insight and clarity of judgment that Josephine brings are unmatched. Joe is not only a visionary in drug delivery but also a trusted partner in our initiatives through Focal Medical and PinPrint. Their expertise will help us to continually evolve our programs and create long-term value."

Their strategic insights will integrate seamlessly with the existing board members, which includes co-founders Bob Whitehead and Ramakrishna Venugopalan, PhD, alongside Monica Reed, MD, Mike Fowler, and Allen Weiss, each bringing their own wealth of experience from various sectors.

Continuity Biosciences: A Brief Overview

Established in 2024, Continuity Biosciences is dedicated to developing advanced drug administration platforms for complex therapies and biologics, with a focus on precision targeting and adjustable release mechanisms. The company operates out of multiple locations including Houston (Texas), Raleigh (North Carolina), Bradenton (Florida), and Turin (Italy). Their product range addresses oncology, metabolic diseases, infectious diseases, and women’s health, leveraging strategic acquisitions like Focal Medical and investments in innovative businesses such as PinPrint to build differentiated platforms.

Conclusion

With the integration of Josephine M. Torrente and Joseph M. DeSimone into the board, Continuity Biosciences is poised for innovative advancements in the field of drug delivery. Their backgrounds not only enhance the regulatory and technological facets of the company but also exemplify its commitment to advancing healthcare solutions for complex medical needs.